Source: FinanzNachrichten

Acousia Therapeutics: Acousia Therapeutics GmbH: Acousia Therapeutics to present its first-in-class hearing loss treatment program with ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston

TÜBINGEN, Germany, May 11, 2022 /PRNewswire/ -- Acousia Therapeutics GmbH will be presenting data on the company's clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd Inne...

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
1-25
Tim Boelke's photo - CEO of Acousia

CEO

Tim Boelke

CEO Approval Rating

90/100

Read more